A dedicated team of highly skilled scientists of various disciplines carry out the toxicology studies. GLP compliant bioanalytical method validations and bioanalysis are performed to support preclinical toxicology studies. GLP method validations and analysis activities are performed for formulations that are used in non-clinical safety studies.
Our vivarium is an AAALAC accredited facility and the clinical pathology analyses and histopathology procedures are performed in state-of-the-art laboratories. Rodent toxicity studies are conducted in rats and mice, repeat dose toxicity studies are performed for a definitive period of test article administration with or without a recovery period.
Our state-of-the-art toxicology services facility is GLP certified by National GLP Monitoring Authority (NGCMA) of India. We provide repeat dose 4-day, 7-day or 14-day dose range DRF toxicity studies performed in rats and mice. The objectives of these studies are to identify the toxic effects upon specific period of exposure and to determine the MTD and No-Observed-Adverse -Effect-Level (NOAEL). The findings of the DRF studies are used for selection of dosage regimen for the subsequent long term or definitive GLP toxicology studies in rats and mice.
We offer a wide range of exploratory toxicology studies such as single dose toxicity study, 4-day, 7-day, or 14-day repeat dose toxicity study to determine the MTD and/or NOAEL upon a short period of exposure through the intended clinical route of exposure in human.
Study designs are customized to the client requirements based on the nature of the test compounds and intended product development program. The end points typically include mortality checks, clinical signs observations, body weight and feed intake measurements, clinical pathology, gross pathology observations, and limited histopathology.
We perform GLP toxicology studies in rats and mice for supporting IND and ANDA submissions. These studies include subacute (ranging from 14 to 28 days), subchronic (90 days) and chronic (180 days to 2 years) toxicity studies. Studies are conducted as per the relevant regulatory guidelines (FDA, OECD, ICH, MHRA etc.,) in AAALAC accredited animal facilities. The end points of the GLP repeated dose toxicity studies include mortality checks, observation of clinical signs of toxicity, body weight and food consumption measurements, interim/terminal clinical pathology (hematology, limited or comprehensive clinical pathology, urinalysis etc.), gross pathology and limited or comprehensive histopathology.
The in-life phase of these studies are performed by a group of highly experienced toxicologists in AAALAC accredited animal facilities. Our clinical pathology and the histopathology lab is equipped with GLP compliant instruments from internationally reputed suppliers. The computerized systems used in the laboratories are validated and fit for purpose as required by the Principles of GLP.
As required by the study design, satellite toxicokinetic (TK) groups are added to obtain plasma drug exposure at scheduled intervals (e.g., first and last days of dosing). To support formulation analysis and bioanalysis, the Toxicology laboratory coordinates with GLP compliant Analytical and DMPK facilities.
The end points of the DRF toxicity studies include mortality checks, observation of clinical signs of toxicity, body weight and food consumption measurements, terminal clinical pathology (hematology, limited or comprehensive clinical pathology, urinalysis etc.), gross pathology and limited or comprehensive histopathology. As required by the study design, satellite toxicokinetic (TK) groups are added to obtain plasma drug exposure at scheduled intervals (e.g., first and last days of dosing). Based on client requirement, analysis of dose formulation samples will be included to estimate the drug concentration verification and homogeneity analysis. To support formulation analysis and bioanalysis, the Toxicology laboratory coordinates with GLP compliant Analytical and DMPK facilities located within the premises.
The in-life phase of these studies are performed by a group of highly experienced toxicologists in AAALAC accredited animal facilities. Our clinical pathology and the histopathology labs are state-of-the-art facilities equipped with GLP compliant instruments from internationally reputed suppliers. The computerized systems used in these laboratories are validated and fit for purpose as required by the principles of GLP.
The main objectives of the single dose Maximum Tolerated Dose (MTD) studies is to determine the maximum dose level that is tolerated by the test species and to determine the dose levels for the subsequent repeat dose toxicity studies by the intended clinical / therapeutic exposure. In the absence of a relevant literature/data for a specific highest test dose, we test up to 2000 mg/kg as a limit dose in line with the recommendations of various international guidelines for conducting acute toxicity studies.
The study is conducted by assigning rats or mice into different treatment groups and exposing them to various graded dose levels to ascertain the toxicity at each dose level and determine the MTD. Essentially, the study end points cover mortality checks (at least twice daily), clinical signs examination for identification of evident toxicity (routine/detailed), body weight and food consumption measurements, gross pathology and as required by the study protocol and a limited histopathology.
We also conduct extended Single dose toxicity studies as per ICH guidelines that include, clinical pathology (hematology, clinical biochemistry & comprehensive histopathology) in addition to the above stated study end points. Formulation analysis for the GLP toxicity studies are performed as required by the client.
FDA, OECD, ICH, MHRA regulatory guidelines
Highly experienced and expert toxicology and analytical scientists
AAALAC accredited animal facilities
State-of-the-art facilities equipped with GLP compliant instruments
Wide range of Toxicology services
JULY 02, 2021
Oligonucleotides as a therapeutic class is a revolutionary approach to discover new and important therapeutic agents for treating human diseases. RNA-based intervention at times works in cases where other modalities do not work. For example, it may help in treating inborn errors in metabolism, genetic disorders and rareOligonucleotide therapeutics is the use of c...Read More
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....Read More
Aurigene Pharmaceutical Services off end-to-end formulation development and manufacturing services fm pr-formulations, clinical development, clinical supplies to commercial manufacturing. ...Read More
Project Challenge: Existing formulation (lower strength - 50 mg) was manufactured using direct compression process. This formulation posed poor powder flow and content uniformity issues during scale-up. Development of new strength 150 mg without any process issues was a challenge. Solution design: Preliminary pre-formulation, stress study and PSD impact assessmen...Read More
A robust and metal catalyst-free method has been developed for the general and green synthesis of racemic (3,4-dihydro-2H-benzo[b][1,4] oxazin-2-yl)methanol derivatives. This simple, mild and practical method involves the reaction of 2-aminophenols with ()-epichlorohydrin in the presence of NaOH in water at room temperature. The reaction features high regioselec...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.